Hyaluronidase Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented By Type (Animal-derived Hyaluronidase, Synthetic Hyaluronidase), By Application and Geography.

Market Snapshot

Hyaluronidase Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The hyaluronidase market is expected to register a CAGR of 8.5% during the forecast period. Factors such as rising awareness about the change of physical appearance have led to the increasing demand for cosmetics and aesthetics procedures. The demand for hyaluronidase in cosmetic dermatology is increasingly driven by the rise in the prevalence of skin disorders and easy access to advanced cosmetic treatments. Moreover, rising penetration across various application areas and the presence of several clinical studies to determine the efficacy of the products are driving the hyaluronidase market. Moreover, the use of enzyme-based substrate for noninvasive tumor imaging in cancer metastasis, numerous applications in cancer therapy, cosmetic treatments, and ophthalmic therapeutic solutions are also key driving factors in the market. Furthermore, rise in the number of people opting for aesthetic non-surgical procedures, rising geriatric population, and favorable reimbursement policies are also expected to fuel the hyaluronidase market. However, Adverse effects associated with hyaluronidases like skin rashes, unusual weakness may hamper the market.

Scope of the Report

A hyaluronidase are enzymes that catalyze the degradation of hyaluronic acid and enhanced permeability of connective tissues. These enzymes are widely used in aesthetic procedures. Hyaluronidase market is segmented by type, by application and geography.

By Type
Animal-derived Hyaluronidase
Synthetic Hyaluronidase
By Application
Chemotherapy
In Vitro Fertilization
Ophthalmology
Dermatology
Others (Plastic surgery)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Animal-derived hyaluronidase Segment is Expected to Contribute a Major Market Share in the Hyaluronidase Market

Animal-derived hyaluronidase is contributing to high market share attributing to most of the approved and commercialized brands are derived from animal sources only. Bovine and porcine are some of the widely used animal sources. Hydase (PrimaPharma), Vitrase (Bausch &Lomb Incorporated) and Amphadase(Amphastar Pharmaceuticals, Inc.) are some of the brands manufactured by manufacturers. Moreover, The animal-derived hyaluronidase market has witnessed a substantial number of product approvals leading to promote the growth of the market. For instance, Genentech received FDA approval for Herceptin hylecta which is a subcutaneous injection in which intravenous Herceptin® (trastuzumab) and recombinant human hyaluronidase PH20 enzyme help to deliver trastuzumab to the skin for the treatment of breast cancer patients, hence the market is expected to witness healthy CAGR over the forecast period.

key trends HM.png

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global hyaluronidase market due to the presence of major players manufacturing these products, high adoption of advanced treatment options and a substantial number of dermatology clinics prescribing such treatments. Moreover, increasing healthcare expenditure and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Asia Pacific region is anticipated to witness a lucrative opportunity as a consequence of medical tourism for dermatology treatments and chemotherapy applications. The presence of a substantial number of suppliers with the advent of technology in South Korea is expected to drive the hyaluronidase market. For instance, in 2018, Alteogen developed the world's second recombinant human hyaluronidase protein and patented protein engineering technology.

Hyaluronidase Market.png

Competitive Landscape

The hyaluronidase market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are PrimaPharma, Inc, Amphastar Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Halozyme, Inc., Sun Pharmaceutical Industries Ltd, STEMCELL Technologies, Inc. and CooperSurgical Fertility and Genomic Solutions.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Penetration of Hyaluronidase in Correction Procedures

      2. 4.2.2 Rising Demand for Minimally Invasive Aesthetic Treatments

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Effects associated with Hyaluronidases

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type

      1. 5.1.1 Animal-derived Hyaluronidase

      2. 5.1.2 Synthetic Hyaluronidase

    2. 5.2 By Application

      1. 5.2.1 Chemotherapy

      2. 5.2.2 In Vitro Fertilization

      3. 5.2.3 Ophthalmology

      4. 5.2.4 Dermatology

      5. 5.2.5 Others (Plastic surgery)

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 PrimaPharma, Inc

      2. 6.1.2 Amphastar Pharmaceuticals, Inc.

      3. 6.1.3 Bausch & Lomb Incorporated

      4. 6.1.4 Halozyme, Inc.

      5. 6.1.5 Sun Pharmaceutical Industries Ltd

      6. 6.1.6 STEMCELL Technologies, Inc.

      7. 6.1.7 The Cooper Companies, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The undefined market is studied from 2018 - 2026.

The undefined is growing at a CAGR of 8.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

PrimaPharma, Inc, Amphastar Pharmaceuticals, Inc, Bausch & Lomb Incorporated, Halozyme, Inc., Sun Pharmaceutical Industries Ltd are the major companies operating in undefined.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!